Adaptive Biotechnologies to Participate in Upcoming Investor Conferences

Rhea-AI Summary

Adaptive Biotechnologies (Nasdaq: ADPT) will participate in two investor conferences in early 2026: the BTIG 13th Annual MedTech, Digital Health, Life Science & Diagnostic Tools Conference in Snowbird, UT on Tuesday, February 10, 2026, and a Fireside chat at the TD Cowen 46th Annual Health Care Conference in Boston, MA on Monday, March 2, 2026 at 11:50 a.m. ET.

Interested parties may access live and archived webcasts of both sessions via the Investors section of the company website at www.adaptivebiotech.com.

News Market Reaction

+0.58%

1 alert

+0.58% News Effect

On the day this news was published, ADPT gained 0.58%, reflecting a mild positive market reaction.

Data tracked by StockTitan Argus on the day of publication.

SEATTLE, Jan. 27, 2026 (GLOBE NEWSWIRE) -- Adaptive Biotechnologies Corporation (Nasdaq: ADPT), a commercial stage biotechnology company that aims to translate the genetics of the adaptive immune system into clinical products to diagnose and treat disease, today announced it will be participating in the following investor conferences.

• BTIG 13^th Annual MedTech, Digital Health, Life Science & Diagnostic Tools Conference in Snowbird, UT
  Participating on Tuesday, February 10, 2026
• TD Cowen 46^th Annual Health Care Conference in Boston, MA
  Fireside chat on Monday, March 2, 2026, at 11:50 a.m. Eastern Time

Interested parties may access live and archived webcasts of the session on the “Investors” section of the company website at: www.adaptivebiotech.com.

About Adaptive Biotechnologies

Adaptive Biotechnologies (“we” or “our”) is a commercial-stage biotechnology company focused on harnessing the inherent biology of the adaptive immune system to transform the diagnosis and treatment of disease. We believe the adaptive immune system is nature’s most finely tuned diagnostic and therapeutic for most diseases, but the inability to decode it has prevented the medical community from fully leveraging its capabilities. Our proprietary immune medicine platform reveals and translates the massive genetics of the adaptive immune system with scale, precision and speed. We apply our platform to partner with biopharmaceutical companies, inform drug development, and develop clinical diagnostics across our two business segments: Minimal Residual Disease (MRD) and Immune Medicine. Our commercial products and clinical pipeline enable the diagnosis, monitoring, and treatment of diseases such as cancer and autoimmune disorders. Our goal is to develop and commercialize immune-driven clinical products tailored to each individual patient.

ADAPTIVE INVESTORS
Karina Calzadilla, Vice President, Investor Relations and FP&A
201-396-1687
investors@adaptivebiotech.com

ADAPTIVE MEDIA
Erica Jones, Associate Corporate Communications Director
206-279-2423
media@adaptivebiotech.com

FAQ

When will Adaptive Biotechnologies (ADPT) present at the BTIG conference?

Adaptive Biotechnologies will present at the BTIG conference on Tuesday, February 10, 2026.

What is the date and time for Adaptive Biotechnologies (ADPT) fireside chat at TD Cowen 2026?

The fireside chat is scheduled for Monday, March 2, 2026 at 11:50 a.m. Eastern Time.

How can investors watch Adaptive Biotechnologies (ADPT) presentations from these conferences?

Live and archived webcasts will be available in the Investors section of the company's website at www.adaptivebiotech.com.

Will the Adaptive Biotechnologies (ADPT) conference webcasts be archived for later viewing?

Yes; the company indicated that both live and archived webcasts will be accessible on its investor website.

Which conferences will Adaptive Biotechnologies (ADPT) attend in early 2026?

ADPT will attend the BTIG 13th Annual MedTech, Digital Health, Life Science & Diagnostic Tools Conference and the TD Cowen 46th Annual Health Care Conference.